M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Phase 1

Active, not recruiting

Conditions: Recurrent Chronic Myelomonocytic Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Chronic Myelomonocytic Leukemia
Refractory Myelodysplastic Syndrome
Therapy-Related Myelodysplastic Syndrome

Interventions: Drug: Azacitidine
Drug: Venetoclax

First Posted Date: 2020-09-16

Last Posted Date: 2024-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 34

Registration Number: NCT04550442

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors

Recruiting

Conditions: COVID-19 Infection
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions: Other: Quality-of-Life Assessment
Other: Survey Administration

First Posted Date: 2020-09-16

Last Posted Date: 2024-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 600

Registration Number: NCT04551378

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors

Not Applicable

Completed

Conditions: Central Nervous System Neoplasm
Metastatic Malignant Solid Neoplasm
Glioma
Metastatic Malignant Neoplasm in the Central Nervous System

Interventions: Procedure: 7 Tesla Magnetic Resonance Imaging
Other: Questionnaire Administration

First Posted Date: 2020-09-07

Last Posted Date: 2025-01-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT04539574

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Validation of Pre-clinical Nano-Based Analgesics in Cells From Human Dorsal Root Ganglia

Recruiting

Conditions: Spinal Cord Neoplasm

Interventions: Procedure: Biospecimen Collection

First Posted Date: 2020-09-01

Last Posted Date: 2024-03-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT04533919

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

Phase 2

Terminated

Conditions: Refractory Malignant Peripheral Nerve Sheath Tumor
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Recurrent Neuroblastoma
Recurrent Rhabdomyosarcoma
Refractory Malignant Solid Neoplasm
Desmoplastic Small Round Cell Tumor
Recurrent Malignant Peripheral Nerve Sheath Tumor
Refractory Desmoplastic Small Round Cell Tumor
Recurrent Desmoplastic Small Round Cell Tumor
Recurrent Malignant Solid Neoplasm

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclosporine
Drug: Etoposide
Drug: Fludarabine Phosphate
Biological: Lapine T-Lymphocyte Immune Globulin
Drug: Melphalan
Drug: Mycophenolate Mofetil
Drug: Tacrolimus
Drug: Thiotepa

First Posted Date: 2020-08-28

Last Posted Date: 2024-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT04530487

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

Phase 1

Terminated

Conditions: Recurrent T-Cell Prolymphocytic Leukemia
Recurrent Acute Biphenotypic Leukemia
Refractory Acute Myeloid Leukemia
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Refractory Acute Biphenotypic Leukemia
Refractory T-Cell Prolymphocytic Leukemia
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Acute Lymphoblastic Leukemia
Refractory Acute Lymphoblastic Leukemia
Recurrent Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Fludarabine
Drug: Pegcrisantaspase

First Posted Date: 2020-08-26

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT04526795

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma

Phase 1

Active, not recruiting

Conditions: Clinical Stage IVA Gastric Cancer AJCC v8
Gastric Adenocarcinoma
Postneoadjuvant Therapy Stage I Gastric Cancer AJCC v8
Clinical Stage III Gastric Cancer AJCC v8
Pathologic Stage IIIC Gastric Cancer AJCC v8
Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8
Pathologic Stage IB Gastric Cancer AJCC v8
Pathologic Stage IIB Gastric Cancer AJCC v8
Pathologic Stage IIIB Gastric Cancer AJCC v8
Postneoadjuvant Therapy Stage II Gastric Cancer AJCC v8

Interventions: Drug: Capecitabine
Drug: Fluorouracil
Radiation: Radiation Therapy
Procedure: Therapeutic Surgical Procedure

First Posted Date: 2020-08-24

Last Posted Date: 2024-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT04523818

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer

Phase 1

Withdrawn

Conditions: Central Nervous System Germ Cell Tumor
Malignant Glioma
Primitive Neuroectodermal Tumor
Recurrent Medulloblastoma
Anaplastic Ependymoma
Atypical Teratoid/Rhabdoid Tumor
Intracranial Myeloid Sarcoma
Recurrent Anaplastic Ependymoma
Recurrent Primitive Neuroectodermal Tumor
Choroid Plexus Carcinoma

Interventions: Drug: Etoposide
Drug: Fludarabine Phosphate
Procedure: Hematopoietic Cell Transplantation
Biological: Lapine T-Lymphocyte Immune Globulin
Drug: Melphalan
Drug: Mycophenolate Mofetil
Drug: Tacrolimus
Drug: Thiotepa

First Posted Date: 2020-08-21

Last Posted Date: 2024-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT04521946

Studying Changes in Physical Function Measures in Stem Cell Transplant Patients at Risk for Steroid Myopathy

Not Applicable

Terminated

Conditions: Acute Graft Versus Host Disease

Interventions: Behavioral: Exercise Intervention
Other: Physical Performance Testing
Other: Questionnaire Administration

First Posted Date: 2020-08-21

Last Posted Date: 2021-04-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT04521777

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

Phase 1

Active, not recruiting

Conditions: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
Localized Gastroesophageal Junction Adenocarcinoma
Locally Advanced Gastroesophageal Junction Adenocarcinoma
Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8

Interventions: Drug: Docetaxel
Drug: Fluorouracil
Drug: Oxaliplatin
Biological: Pembrolizumab
Radiation: Radiation Therapy

First Posted Date: 2020-08-21

Last Posted Date: 2024-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT04522336

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Home Terms & Conditions Privacy Policy